Vivos Therapeutics at the NIBA Conference

A few months ago in March, Vivos Therapeutics, one of the world leaders in the treatment of obstructive sleep apnea had the pleasure of being a featured presenter at the National Investment Bankers Association (NIBA) conference which was held in New York City at the Westin Hotel in Times Square. Presenting at this conference was their chief executive officer, R. Kirk Huntsman, and Ed Loew, who is the senior vice president, and capital markets and investor relations.

Vivos has been deploying a highly effective, interdisciplinary clinical treatment for those who are suffering from mild to moderate obstructive sleep apnea, and this treatment features their proprietary line of unique oral appliances. This condition affects about 29 million adults daily and there is also an additional 22 million children that could be at risk. It is most common amongst men, especially middle-aged and overweight men. In fact, in totality, one in every seven Americans suffer directly from sleep apnea.

The Vivos System, developed by Huntsman and his co-founder Dr. Dave Singh is a breakthrough technology and treatment for obstructive sleep apnea (OSA) and could possibly be the first legitimate long-term solution to addressing the major root cause of the disorder which is an underdeveloped or obstructed airway. The majority of solutions to OSA look to treat the symptoms through pressure or force. Vivos, on the other hand, gently remodels the upper airway by slowly developing and repositioning the jaws which restore healthy sleep and breathing. Plus, many of the common treatments like CPAP require lifetime use and nightly wear, whereas the Vivos System usually lasts 12-24 months and allows patients to avoid any further clinical intervention.

According to Huntsman, “As we strive to bring the Vivos System to more people across the country, thus positively impacting the lives of apnea sufferers and their families, we believe it is critical to bring information about the company to the investing community. That is partly how we will be able to bring relief to millions of OSA patients, both diagnosed and as yet undiagnosed.”

For more information, please visit